Proveca focuses on the re-engineering of existing generic medicines to make them appropriate for use by young people. The company is developing and commercialisng medicines for children in the fields of cardiology, neurology and pain management.
Albion portfolio company Proveca has received a positive opinion from the EMA CHMP on their lead compound Sialanar
Proveca gains fourth key agreement with EMA
ALBION VENTURES INVESTS £2.6M IN PHARMA FIRM PROVECA
PROVECA GAINS FOURTH KEY AGREEMENT WITH EMA